This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.